Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $2.2 million.

  • Seres Therapeutics' Free Cash Flow rose 106.31% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 85.25%. This contributed to the annual value of -$149.0 million for FY2024, which is 18.88% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Free Cash Flow is $2.2 million, which was up 116.34% from -$13.4 million recorded in Q2 2025.
  • Seres Therapeutics' Free Cash Flow's 5-year high stood at $123.7 million during Q3 2021, with a 5-year trough of -$80.7 million in Q1 2023.
  • Over the past 3 years, Seres Therapeutics' median Free Cash Flow value was -$35.3 million (recorded in 2024), while the average stood at -$23.5 million.
  • Data for Seres Therapeutics' Free Cash Flow shows a peak YoY increase of 576.82% (in 2021) and a maximum YoY decrease of 194.39% (in 2021) over the last 5 years.
  • Seres Therapeutics' Free Cash Flow (Quarterly) stood at -$53.4 million in 2021, then fell by 5.45% to -$56.4 million in 2022, then climbed by 14.16% to -$48.4 million in 2023, then grew by 19.44% to -$39.0 million in 2024, then surged by 106.31% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, -$13.4 million for Q2 2025, and $26.9 million during Q1 2025.